HR-defective cells, including BRCA2-defective cancer cells, exhibit profound sensitivity to inhibitors of poly(ADP-ribose) polymerase (PARP); hence, cancers harboring mutations in BRCA2 can be treated effectively with PARP inhibitors (Bryant et al., 2005; Farmer et al., 2005). This evidence concerns the gene PARP1 and cancer.